News
-
Demographics Favoring Growth Of Cardiac Imaging Modalities Market
1/2/2013
Manufacturers to focus on innovative, easy-to-use and patient-friendly products due to a shift in the adoption pattern for imaging modalities.
-
Zafgen Announces Initiation Of Phase 2a Clinical Development With Beloranib In Obesity
11/6/2012
Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that it has initiated Phase 2a clinical testing of beloranib.
-
Second Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome
10/12/2012
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line data from a recently completed Phase 2 study in carcinoid syndrome with telotristat etiprate.
-
Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical Trial Of APD811 For Pulmonary Arterial Hypertension
10/12/2012
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).
-
First Results From Phase 3 CANVAS Trial Show Canagliflozin As Add-on Therapy To Insulin Lowered Blood Sugar Levels In Patients With Type 2 Diabetes At An Elevated Risk For Cardiovascular Disease
10/2/2012
Janssen Research & Development, LLC (Janssen) today announced that use of the investigational medicine canagliflozin substantially lowered blood glucose levels when used as add-on therapy in patients on insulin therapy for type 2 diabetes and who are considered to be at greater risk for cardiovascular disease.
-
Kinexum And Pennington Biomedical Announce Collaboration For Accelerating Clinical Research Innovation
9/24/2012
Kinexum and Pennington Biomedical Research Center announced plans to establish an integrated approach for emerging companies and early stage therapies to achieve high value regulatory and early phase human clinical trials.
-
Hybrigenics Starts Phase II Clinical Trial Of Inecalcitol In Chronic Lymphocytic Leukemia
9/11/2012
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext in Paris, with a focus on research and development of new treatments against proliferative diseases, recently announces the start of a phase II clinical trial of oral inecalcitol in patients with chronic lymphocytic leukemia (CLL).
-
Daiichi Sankyo And Lilly Announce TRILOGY ACS Results Regarding Effient (Prasugrel) In Acute Coronary Syndrome UA/NSTEMI Patients To Be Managed Medically Without An Artery-Opening Procedure
8/26/2012
Daiichi Sankyo Company, Limited, and Eli Lilly and Company recently announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI), who were managed medically without an arteryopening procedure.
-
ActiGraph Introduces First Wireless Activity Monitor
7/12/2012
ActiGraph has announced the release of the wGT3X+ activity monitor, the first wireless device from the industry’s leading provider of objective 24 hour physical activity and sleep/wake monitoring hardware and software solutions.
-
Isis Initiates Phase 2 Study Of ISIS-APOCIIIRx In Patients With Hypertriglyceridemia
5/4/2012
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APOCIIIRx in patients with hypertriglyceridemia. Hypertriglyceridemia, a condition characterized by high levels of triglycerides, is often associated with premature coronary artery disease and pancreatitis.